(Reuters) -McKesson said on Thursday it will restructure its operations into four main segments from the current quarter as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.
The restructuring will reflect how CEO Brian Tyler will allocate resources and assess performance going forward, but does not affect previously issued financial statements or historical earnings per share, the company said.
“This updated reporting structure reflects a strategic evolution of our business – accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services,” Chief Financial Officer Britt Vitalone said in a statement.
Starting this quarter, its second in fiscal 2026, the Texas-based firm will reorganize into North American pharmaceutical, oncology and multispecialty, prescription technology solutions, and medical-surgical solutions segments, the company said.
The pharmaceutical segment will combine McKesson’s wholesale drug distribution businesses in the U.S. and Canada, while the oncology and multispecialty segment will cater to cancer care networks and other specialty providers such as in ophthalmology.
The restructuring is a “prudent move” as it helps investors understand the company’s growth drivers, with the oncology segment being the most significant disclosure, Leerink Partners analyst Michael Cherny said.
Prescription technology solutions will connect patients, pharmacies, and healthcare providers through its networks.
The medical-surgical solutions segment will provide medical supply distribution and logistics services to healthcare providers. McKesson had announced plans to spin off this segment into an independent company in May.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
Comments